Cargando…

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma

BACKGROUND: Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer overexpressing HER2/neu in about 30% of cases. Trastuzumab, a humanized monoclonal antibody targeting Her2/Neu, in combination with carboplatin/paclitaxel, is considered the preferred regimen for the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pelligra, Silvia, Buza, Natalia, Hui, Pei, Bellone, Stefania, Zeybek, Burak, Ratner, Elena, Schwartz, Peter E., Scambia, Giovanni, Santin, Alessandro D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049633/ https://www.ncbi.nlm.nih.gov/pubmed/32140533 http://dx.doi.org/10.1016/j.gore.2020.100554

Ejemplares similares

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
por: Santin, Alessandro D., et al.
Publicado: (2016)

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
por: Todeschini, P, et al.
Publicado: (2011)

Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management
por: Lopez, Salvatore, et al.
Publicado: (2018)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy
por: Bellone, S, et al.
Publicado: (2012)

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
por: El-Sahwi, K, et al.
Publicado: (2010)

Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy
por: McNamara, Blair, et al.
Publicado: (2023)

T-DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo
por: English, Diana P, et al.
Publicado: (2014)

BET inhibitors: Betting on improved outcomes in uterine serous carcinoma
por: Zeybek, Burak, et al.
Publicado: (2018)

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo
por: Schwab, C L, et al.
Publicado: (2014)

Improved survival of patients with hypermutation in uterine serous carcinoma
por: Santin, Alessandro D., et al.
Publicado: (2015)

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer
por: Perrone, Emanuele, et al.
Publicado: (2020)

Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer
por: Cocco, E, et al.
Publicado: (2009)

Clinicopathological Characteristics and Her-2/neu Status in Chinese Patients with Uterine Papillary Serous Carcinoma
por: Ren, Yulan, et al.
Publicado: (2011)

HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma
por: McNamara, Blair, et al.
Publicado: (2023)

erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy
por: ElSahwi, Karim S., et al.
Publicado: (2011)

Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas
por: Lopez, Salvatore, et al.
Publicado: (2020)

Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report
por: Han, Chanhee, et al.
Publicado: (2018)

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo
por: Cocco, Emiliano, et al.
Publicado: (2016)

Combined trastuzumab and radiation therapy for HER2-positive uterine serous carcinoma: A case report
por: Mao, SPH, et al.
Publicado: (2023)

Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo
por: Perrone, Emanuele, et al.
Publicado: (2020)

Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
por: Santin, A D, et al.
Publicado: (2005)

Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
por: Stanton, Sasha E, et al.
Publicado: (2015)

hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma
por: Cocco, E, et al.
Publicado: (2010)

Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling
por: Santin, A D, et al.
Publicado: (2004)

The Predictive Value of Serum HER2/neu for Response to Anthracycline-Based and Trastuzumab-Based Neoadjuvant Chemotherapy
por: Lee, Jung Sun, et al.
Publicado: (2012)

Plant-Made Trastuzumab (Herceptin) Inhibits HER2/Neu+ Cell Proliferation and Retards Tumor Growth
por: Komarova, Tatiana V., et al.
Publicado: (2011)

Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature
por: Firwana, Belal, et al.
Publicado: (2012)

Computational model to explore the endocrine response to trastuzumab action in HER-2/neu positive breast cancer
por: Wang, Fuzhang, et al.
Publicado: (2022)

Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment
por: Han, Chanhee, et al.
Publicado: (2018)

Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody
por: Raji, Rhoda, et al.
Publicado: (2011)

High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma
por: Damast, Shari, et al.
Publicado: (2015)

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan
por: Zeybek, Burak, et al.
Publicado: (2020)

Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance
por: Carvajal-Hausdorf, Daniel E., et al.
Publicado: (2017)

Societal Costs and Benefits of Treatment with Trastuzumab in Patients with Early HER2neu-Overexpressing Breast Cancer in Singapore
por: de Lima Lopes, Gilberto
Publicado: (2011)

Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?
por: Sbitti, Yassir, et al.
Publicado: (2011)

Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells
por: Baumann, Jan, et al.
Publicado: (2016)

cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma
por: Semiz, Huseyin Salih, et al.
Publicado: (2023)

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
por: McNamara, Blair, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v2s2b4v4tqqts8jtpbojv6apk8